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Essentials
• Factor IX (FIX) dosing using body weight frequently
results in under and overdosing during surgery.
• We aimed to establish a population pharmacokinetic
(PK) model describing the perioperative FIX levels.
• Population PK parameter values for clearance and V1
were 284 mL h170 kg1 and 5450 mL70 kg1.
• Perioperative PK parameters differ from those during
non-surgical prophylactic treatment.
Summary. Background: Hemophilia B is a bleeding dis-
order characterized by a deficiency of coagulation factor
IX (FIX). In the perioperative setting, patients receive
FIX concentrates to ensure hemostasis. Although FIX
is usually dosed according to bodyweight, under- and
overdosing occurs frequently during surgery. Aim: The
objective was to quantify and explain the interpatient
variability of perioperatively administered plasma-
derived (pd) and recombinant (r) FIX concen-
trates. Methods: Data were collected from 118 patients
(median age, 40 years [range, 0.2–90]; weight, 79 kg
[range, 5.3–132]) with moderate (28%) or severe hemo-
philia B (72%), undergoing 255 surgical procedures.
Population pharmacokinetic (PK) parameters were esti-
mated using nonlinear mixed-effect modeling in NON-
MEM. Results: Measured perioperative FIX level vs.
time profiles were adequately described using a three-
compartment PK model. For a typical 34-year-old
patient receiving rFIX, clearance (CL), intercompart-
mental clearance (Q2, Q3), distribution volume of the
central compartment (V1) and peripheral compartments
(V2, V3) plus interpatient variability (%CV) were: CL,
284 mL h170 kg1 (18%); V1, 5450 mL70 kg1 (19%);
Q2, 110 mL h170 kg1; V2, 4800 mL70 kg1; Q3,
1610 mL h170 kg1; V3, 2040 mL70 kg1. From
0.2 years, CL and V1 decreased 0.89% and 1.15% per
year, respectively, until the age of 34 years. Patients
receiving pdFIX exhibited a lower CL (11%) and V1
(17%) than patients receiving rFIX. Interpatient vari-
ability was successfully quantified and explained. Con-
clusions: The estimated perioperative PK parameters of
both pdFIX and rFIX are different from those reported
for prophylactic treatment. The developed model may
be used to apply PK-guided dosing of FIX concentrates
during surgery.
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Introduction
Hemophilia B is a bleeding disorder characterized by a
deficiency of coagulation factor IX (FIX). Severe and mod-
erate patients have endogenous FIX levels less than
0.01 IU mL1 and between 0.01 and 0.05 IU mL1,
respectively [1,2]. In this category of patients, plasma-
derived FIX (pdFIX) or recombinant FIX (rFIX) standard
half-life concentrates are usually administered prophylacti-
cally to prevent spontaneous joint and muscle bleedings
[3,4] and ‘on-demand’ when bleeding occurs in the surgical
setting. In the prophylactic setting, FIX trough levels
above 0.01 IU mL1 are usually aimed for, as moderate
patients have significantly fewer spontaneous bleeds [5]. In
the perioperative setting, higher doses of FIX concentrates
are administered to normalize FIX levels for 7–10 consecu-
tive days post-surgery, with target trough levels from 1.00
to 0.30 IU mL1 ensuring adequate hemostasis [6].
Currently, prophylactic, ‘on-demand’ and perioperative
dosing of FIX concentrates is performed according to
bodyweight with frequent monitoring to ensure sufficient
FIX levels. Despite weight-based dosing, considerable
under- and overdosing in the surgical setting has been
reported by Hazendonk et al. [7]. It was shown that 60%
of hemophilia B patients have FIX levels below the target
level range during the first 24 h directly after surgery.
This lack of adequate FIX plasma levels confers a consid-
erable potential risk of bleeding and should be avoided.
Therefore, more optimal dosing strategies are warranted.
In the prophylactic setting, FIX doses can be tailored
to an individual’s need by pharmacokinetic (PK)-guided
dosing using Bayesian analysis [8]. In this approach,
observed individual FIX levels are combined with PK
information assessed in the population in order to obtain
estimates for individual PK parameters [9]. These individ-
ual parameter estimates can be used to calculate doses
necessary to achieve and maintain desired target levels by
PK-guided dosing, potentially preventing over- and
under-dosing. This approach can be applied iteratively,
because with every new blood sample the calculated dose
can be adapted to alterations in the individual PK param-
eter estimates [10]. This technique may also be applied in
the perioperative setting.
A prerequisite for applying Bayesian analysis to periop-
erative dosing of FIX is the availability of a population
model that describes the PK of FIX in hemophilia B
patients undergoing surgery. The population PK of pdFIX
and rFIX is well documented [5,11–13]. However, these
models have all been constructed using data during non-
surgical dosing of FIX concentrates. In the perioperative
setting, the PK of FIX may, however, be altered. In order
to apply Bayesian dosing in the perioperative setting, a
dedicated population model should be available.
This study was performed to describe the population
PK of pdFIX and rFIX concentrates in hemophilia B
patients during surgery and the days thereafter. It was
investigated whether specific patient and surgical charac-
teristics explain interpatient variability (IIV) in FIX expo-
sure and whether the perioperative PK of FIX is similar
to the prophylactic situation.
Methods
Patients and clinical data
An international multi-center observational cohort study
was performed in which data were collected from 118 sev-
ere and moderate hemophilia B patients from five Hemo-
philia Treatment Centers in the Netherlands and five in
the United Kingdom. Patients of all ages, who had under-
gone a minor or major elective surgical procedure
between 1 January 2000 and 1 December 2015, were
included [14]. Details of the study data have been
reported previously [7].
In summary, severe and moderate hemophilia B
patients received replacement therapy during surgery with
FIX concentrates according to national and/or hospital
guidelines, while aiming for target FIX levels as pre-
scribed. To ensure hemostasis during the surgical proce-
dure, a pdFIX product (AlphaNine SD [Grifols
Biologicals Inc., Los Angeles, CA, USA], Replenine [Bio
Products Laboratory, Elstree, UK], Haemonine [Biotest
Pharma GmbH, Dreierich, Germany], Mononine [CSL
Behring GmbH, Marbourg, Germany] and Nonafact
[Sanquin, Amsterdam, the Netherlands]) or rFIX product
(BeneFix [Pfizer Wyeth Pharmaceuticals Inc., Kent, UK]
and IXinity [Aptevo BioTherapeutics LLC, Berwyn ,
USA]) was administered with a bolus infusion of approxi-
mately 100 IU kg1, followed by either multiple intermit-
tent bolus infusions or continuous infusions. FIX levels
were obtained in the participating centers using a one-
stage assay, according to local protocol.
Pharmacokinetic modeling
In population PK modeling, the PK is assessed in a
cohort of patients rather than in an individual patient
[15]. In population PK modeling, not only the average or
median value of a PK parameter is of interest but also its
inter- and intra-patient variability. Population PK param-
eters can be obtained by the standard two-stage method,
in which individual PK parameters are calculated and,
subsequently, summarized. A drawback of this method is
that for each individual 10 or more serial samples should
be available (rich sampling). In the clinical situation, this
is often impossible or inconvenient to perform, especially
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in populations such as children or the elderly. An alterna-
tive is the population approach [16], which allows the
estimation of population PK parameters by analyzing
data from all the patients simultaneously. The simultane-
ous analysis allows the use of sparsely and heteroge-
neously sampled data, which are frequently encountered
in the clinical situation. In this study, sparsely and hetero-
geneously sampled data were used to construct the popu-
lation PK model.
Using the population-based approach, a structural PK
model is established first. This model consists of a num-
ber of PK compartments, with PK parameters described
in terms of clearance and volume of distribution. The
structural model provides values for the typical (average)
parameter and, importantly, several levels of variability.
Differences in PK parameters between patients are quan-
tified in terms of interpatient variability (IIV). Variability
of a PK parameter within a patient may be quantified by
estimation of inter-occasion variability (IOV). Further-
more, a population PK model contains residual unex-
plained variability, which is the variability of the
differences between the predicted and the measured
plasma levels. By combining observed individual FIX
levels and population PK parameters, empirical Bayesian
estimates of the individual PK parameters can be
obtained. These empirical Bayesian estimates can be used
in the covariate analysis (below).
In this study, nonlinear mixed-effects modeling was used
to estimate the population PK parameters [17]. A detailed
description of the methods used to construct the popula-
tion PK model can be found in Data S1. For each patient,
the (historically lowest) endogenous baseline level was sub-
tracted from each observed FIX level. Furthermore, in
some subjects, a preoperative FIX level was present that
was higher than the measured endogenous baseline level
and for which no prior dose information was known. In
the modeling procedure, the preoperative level was
accounted for by an arbitrary virtual dose of 8250 IU
administered 5 days prior to the pre-dose FIX measure-
ment. To account for inter- and intra-individual variability
in the observed preoperative FIX levels, the typical
bioavailability of this dose was estimated in combination
with its IIV and IOV. For estimation of the IOV, an occa-
sion was defined as a single surgical procedure.
After the structural model was established, it was eval-
uated whether patient and surgical characteristics (covari-
ates) explained the variability (IIV, IOV and residual
unexplained variability) in a covariate model. Because
FIX levels were available for both children and adults,
estimated PK parameters were normalized for a body-
weight of 70 kg using allometric scaling with the ¾ rule
[18]. Bodyweight was, however, missing in 38 surgical
procedures (14.9%) involving 18 patients (15.3%). There-
fore, a piecewise linear model was developed to impute
the missing values for bodyweight using age as a predic-
tor. Covariate relationships were evaluated using
graphical evaluation of plots of the empirical Bayesian
estimates vs. the covariate value. Subsequently, covariates
were implemented in the population model and their abil-
ity to explain the IIV, IOV or residual unexplained vari-
ability was tested by univariate analysis. The following
covariates were evaluated: severity of hemophilia (severe
vs. moderate), age, the use of tranexamic acid or heparin
during surgery, the type of FIX concentrate (plasma
derived or recombinant), the brand of product, treatment
center, country of treatment, presence of hepatitis C, the
use of prophylaxis before the surgical procedure, a history
of neutralizing inhibitors, having a minor or major surgi-
cal procedure, blood group and the presence of an infec-
tion or a decrease in hemoglobin concentration during
the surgical procedure. The final model, containing multi-
ple covariates, was constructed by multivariate analysis
using forward inclusion and backward deletion.
Model evaluation
The objective function value (OFV), which represents the
ability of the model to describe the observed FIX levels,
was used to discriminate between different models. When
comparing nested models, the difference of the correspond-
ing OFVs (dOFV) is known to be described by a chi-
squared distribution, in which the difference in the number
of parameters between the evaluated models determines the
degrees of freedom. Therefore, a dOFV bigger than 3.84,
5.99 or 7.81 indicates a significant difference of P < 0.05
with 1, 2 or 3 degrees of freedom, respectively. In the
covariate analysis, covariates were selected in the forward
inclusion and backward elimination procedure if dOFVs
bigger than 3.84 (P < 0.05, d.f. = 1) and 6.63 (P < 0.01,
d.f. = 1), respectively, were obtained.
To evaluate whether the measured FIX levels were ade-
quately described by the developed population PK model,
several criteria were used. The adequacy of the model was
evaluated by inspection of precision of the estimated
model parameters, creation of goodness-of-fit plots, evalu-
ation of shrinkage of the IIV, IOV and residual unex-
plained variability, the condition number of the model
and the creation of visual predictive checks [19,20]. In the
latter procedure, FIX levels were generated by Monte
Carlo simulation (n = 1000) using the established popula-
tion PK model and are, subsequently, compared to the
actual measured FIX levels [21]. For the goodness-of-fit
plots, the measured FIX levels were compared with the
population predicted FIX levels using the typical values
for the PK parameters and the individual FIX levels pre-
dicted on basis of the empirical Bayesian estimate. More-
over, several plots were evaluated depicting conditional
weighted residuals (CWRES). CWRES are the weighted
difference between the model-predicted and measured
FIX levels [22].
The stability and robustness of the final model were
tested by a bootstrap analysis [23]. In this analysis, 1000
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis
2198 T. Preijers et al
new datasets were created by randomly sampling from the
data from all patients in the original dataset. Subsequently,
the final model was re-estimated using the bootstrapped
datasets. The median and 95% confidence interval of the
obtained bootstrap parameters were compared with the
estimated PK parameters of the final model.
Comparison with non-surgical FIX models
The final population model describing the PK of FIX in
hemophilia B patients during surgery was compared with
published population PK models derived from data of
patients on prophylaxis [11–13,24]. To evaluate whether
the published prophylactic models were able to describe
the perioperative FIX levels from this study, predictions
of the perioperative FIX levels were calculated using the
prophylactic population PK parameters. For each model,
the difference between the population predictions and the
measured FIX levels was summarized using the relative
mean prediction error (rMPE). The latter was calculated
using the following equation:
rMPE ¼ 1
n
Xn
i¼1
CPRED  CFIX:C
CFIX:C
 
 100% ð1Þ
in which Cpred are the population predictions and CFIX:C
the measured FIX level for a total of n measurements.
Furthermore, the terminal elimination half-life was calcu-
lated using the values from all population PK parameters.
Results
Patients
In total, 118 severe and moderate hemophilia B patients
were included, undergoing 262 surgical procedures. Four
occasions were excluded, as FIX levels were not mea-
sured. Because of the withdrawal of approval for IXinity
by the European Medicine Agency during data collection
in June 2013, another three surgical procedures were also
excluded from analysis [25]. As a result, data from 255
surgical procedures were used for PK analysis. Table 1
shows the general patient characteristics.
Table 1 General characteristics of the study population
Total cohort Adults Children*
N (%) or median [range]
Patient characteristics
No. of patients 118 82 36
Age (years) 40 [0.2–90] 46 [18–90] 6 [0.2–18]
Bodyweight (kg) 79 [5.3–132] 85 [47–132] 19 [5.3–117]
Severe hemophilia B (< 0.01 IU mL1) 85 (72) 57 (70) 28 (78)
On prophylaxis 36 (31) 28 (34) 8 (22)
Blood group O† 33 (28) 24 (29) 9 (25)
Neutralizing antibodies (historically) 6 (5) 5 (6) 1 (3)
Chronic hepatitis C 47 (40) 46 (56) 1 (3)
Patient treated in the UK 93 (79) 63 (77) 30 (83)
Surgical characteristics
No. of surgical procedures 255 201 54
Total no. of patients undergoing:
1 118 82 36
2 63 49 14
3 32 28 4
> 3 42 42 0
Minor surgical procedures 135 (53) 96 (48) 39 (72)
Major surgical procedures 120 (47) 105 (52) 15 (28)
Replacement therapy with FIX concentrate
Mode of infusion
Continuous 56 (22) 54 (27) 2 (4)
Bolus 199 (78) 147 (73) 52 (96)
Product type
Recombinant 201 (79) 150 (75) 51 (91)
Plasma derived 54 (21) 51 (25) 3 (6)
Pharmacokinetic data
Total number of observations 1555 1324 (85) 231 (15)
No. of observations per occasion 4 [1–23] 10 [1–23] 5 [1–16]
No. of doses per occasion 7 [1–52] 12 [1–52] 12 [1–39]
*Children were defined as having an age less than 18 years. †Blood group available in 80 patients. Adapted from Hazendonk et al. [7] with per-
mission.
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Bodyweight was not recorded in 14.9% of all surgical
procedures. Therefore, a piecewise linear model was
developed, from which the missing values for bodyweight
could be imputed using age (Data S1). Table S1 shows
the parameter estimates for the piecewise linear model.
The relationship between age and bodyweight is shown in
Fig. 1; the blue line depicts the predictions from the
model for all ages, which was used to impute values for
the missing bodyweights.
Pharmacokinetic modeling
For constructing the structural model, a three-compart-
ment model more adequately fitted the FIX levels than a
two-compartment model (dOFV = 58.1, P < 0.001) (Fig-
ure S1). Table 2 summarizes the parameter estimates of
the structural model. For all estimated PK parameters,
the imprecision of the estimated value was lower than
20%. A proportional residual error model was most
appropriate to fit the data, as compared with an additive
or combined residual error model. In the structural
model, IIV could be estimated for both CL and V1, as
well as a correlation for the IIV between the two parame-
ters. Moreover, shrinkage values for the IIV of CL and
V1 were lower than 20%, indicating that there was suffi-
cient information available for each patient to estimate
the individual parameters reliably [26]. Although IIV
should also be present for the other PK parameters (e.g.
Q2, Q3, V2, V3), the available data did not support the
estimation of these values. Pre-administration FIX levels
(greater than endogenous baseline values) were present in
138 of the 255 evaluated surgical procedures and ranged
from 0.01 to 0.67 IU mL1. Administration of a virtual
dose of 8250 IU, 120 h before the start of the surgery,
adequately approximated the pre-administration FIX
levels and significantly improved the fit of the model;
dOFV was  495.5 (P < 0.001). The typical value for the
estimated bioavailability of the virtual dose was 99.8%
and IIV and IOV values were 91% and 93%, respectively.
These values indicate that virtual doses vary largely
between patients and surgical procedures, with values
ranging from 744.2 to 196 824.2 IU. Estimation of IOV
for differences in CL and V1 between surgical procedures
was not successful. By implementing IOV for CL, the fit
of the model improved (dOFV,  141.9; P < 0.01). How-
ever, parameter estimates became unstable and IOV was
therefore not included.
Covariate analysis
To prevent the covariates influencing the estimation of
the virtual dose, the IIV and IOV from the virtual dose
were fixed to the values obtained for the structural model.
Table 3 shows the dOFV for the selected covariate rela-
tions from the forward inclusion and backward elimina-
tion procedure. Age of the patient was included for CL
and V1 as a piecewise linear model, which is a linear
model with two slopes. The best fit was obtained when
the first slope was estimated and the second was set to
zero from an age of 34 years, which was the median, and
higher. As a result, the bodyweight-normalized CL and
V1 decreased 0.89% and 1.15% per year, respectively,
until the age of 34 years. Moreover, IIV was reduced
from 20.8% to 18.5% (10.1%) and from 24.6% to 18.7%
(14.6%) for CL and V1 as a result of the introduction of
age. In Fig. 2(A,B), age vs. individual values for CL and
V1, as obtained by Bayesian analysis using the final
model, are shown. In these figures, the combined effect of
bodyweight and age is observed, as CL and V1 increase
with bodyweight and decrease with age up to 34 years.
Patients receiving pdFIX concentrates exhibited a lower
CL and V1 as compared with patients receiving rFIX
concentrates; respective values were 11% and 17% lower
for pdFIX. Moreover, V1 was 10% lower in patients with
moderate hemophilia in comparison to patients with sev-
ere hemophilia. The parameters of the final model are
summarized in Table 2. All other covariate relations did
not result in a significant dOFV.
Evaluation of the final model
The fit of the final model was evaluated by inspection
of goodness-of-fit plots, as shown in Fig. 3(A–D).
Figure 3(A) shows the prediction of FIX levels, based on
the population PK parameter values, adjusted for the
covariate values. Both under- and overprediction are pre-
sent because IIV is not taken into account for calculating
the population predictions. Nevertheless, the population
predictions are distributed randomly around the y = x
axis, demonstrating the appropriateness of the model.
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Fig. 1. Imputed bodyweight vs. age. Black dots are individual body-
weights for 99 patients. The blue line depicts the predicted body-
weight with age as a predictor, as described by the following
piecewise linear model: WTest (kg) = 6.3 + 3.6 9 AGE  3.73 9
(AGE  23.5)DAGE. In this equation, WTest is the estimated body-
weight and DAGE is 1 in the case that the age of the patient is
23.5 years or older; in every other case it is zero. [Color figure can
be viewed at wileyonlinelibrary.com]
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Figure 3(B) is obtained after Bayesian analysis, in which
individual PK parameter estimates are obtained by simul-
taneous analysis of the individual observations and the
population model. The individual FIX levels are predicted
using the derived empirical Bayesian estimates. Again,
these predictions are distributed randomly around the
y = x axis. Figure 3(C,D) shows plots of the conditional
weighted residuals (CWRES) vs. predicted FIX level and
time, respectively. CWRES values are distributed ran-
domly around the line y = 0 (see also Figure S3). Most of
the values are within the  2 and + 2 SD range, which
confirms the goodness-of-fit of the final model.
To evaluate the stability of the final model, a bootstrap
analysis was performed. In this analysis, 1000 model esti-
mations were performed, from which 98.3% were success-
ful. Table 2 shows that the medians for the parameter
estimates from the bootstrap analysis were similar to
those from the final model, except for Q3. This deviation
for Q3 is caused by the high imprecision of its estimation,
as shown by the 95% CI for Q3 from the bootstrap anal-
ysis (667.2–5131.9 mL h170 kg1). For all other parame-
ters of the final model, the CIs were small and
corresponded to the relative standard errors from the
parameter estimates of the final model.
Table 2 Estimated population pharmacokinetic parameters for the structural model, final model and bootstrap analysis
Structural model Final model Bootstrap analysis
Estimate RSE (%) Shr. (%) Estimate 95% CI Shr. (%) Estimate 95% CI
Structural model
Clearance (CL; mL h170 kg1) 296 2.5 284 [266–302] 283 [265–300]
Volume of central compartment
(V1; mL 70 kg1)
5370 2.7 5450 [5005–5895] 5426 [4933–5886]
Distribution clearance to
compartment 2
(Q2; mL h170 kg1)
112 25 110 [86–134] 110 [92–140]
Volume of compartment 2
(V2; mL 70 kg1)
4720 16.7 4800 [3793–5807] 4879 [4118–6367]
Distribution clearance to
compartment 3
(Q3; mL h170 kg1)
2210 19.9 1610 [ 32 to 3252] 1943 [667–5132]
Volume of compartment 3
(V3; mL 70 kg1)
2160 17.7 2040 [1344–2736] 2079 [1376–2753]
Virtual dose 0.998 22.0 ND ND
Inter-individual variability (%CV)
IIV on CL 20.8 9.1 12.3 18.5 [16.4–21.3] 10.2 18.5 [15.3–21.5]
IIV on V1 24.6 12.2 14.5 18.7 [16.5–21.4] 15.0 18.7 [14.0–23.5]
Correlation between
CL and V1 (%)
91.3 11.2 89.4 [85.0–92.5] 89.1 [88.6–91.6]
IIV on virtual dose 94.5 18.0 ND ND
Inter-occasion variability (%CV)
IOV on virtual dose 93.4 10.2 ND ND
Residual variability
Proportional residual
error (%CV)
23.0 4.2 21.9 [20.2–23.6] 21.7 [20.0–23.3]
Covariate relations
CL (% change with age
different from 34 years)
 0.89 [ 1.4 to  0.4] 0.89 [ 1.4 to  0.4]
V1 (% change with age
different from 34 years)
 1.15 [ 1.7 to  0.6] 1.14 [ 1.7 to  0.6]
CL, plasma-derived product (%) 88.8 [83.8–93.8] 88.9 [84.3–94.6]
V1, plasma-derived product (%) 82.7 [74.7–90.7] 82.3 [72.5–90.8]
V1, if moderate
hemophilia patient (%)
89.5 [82.8–96.2] 89.1 [82.3–96.3]
Model characteristics
Objective function value  2827.12  2905.27 ND
Condition number 68.65 119.65 ND
CI, confidence interval as obtained using the 2.5th and 97.5th percentiles from the non-parametric distributions; CV, coefficient of variation;
IIV, interpatient variability; IOV, inter-occasion variability; ND, not determined; RSE, relative standard error; Shr., shrinkage. The typical val-
ues are obtained for a severe hemophilia B patient weighing 70 kg receiving a recombinant factor IX product.
CL mL h1
  ¼ 284  BW70
 0:75
 1 0:0089  Age 34ð Þð ÞAGE\34  0:888Plasmaderived product.
V1 mLð Þ ¼ 5450  BW70
 1:0
 1 0:0115  Age 34ð Þð ÞAGE\34  0:827Plasmaderivedproduct  0:895moderate hemophilia.
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The evaluation of the final model comprised 1000
Monte Carlo simulations for each patient to construct a
visual predictive check, as shown in Fig. 4 (and
Figure S4). The (grey) lines, depicting the 2.5th, 50th and
97.5th percentiles of the measured FIX levels, are pre-
dominantly within their corresponding 95% prediction
Table 3 Model building-steps
OFV dOFV No. of parameters
Structural model
1 Structural model with doses calculated using the virtual dose  2827.1 ND 9
Covariate relationships – forward inclusion
2 Structural model and age on CL*  2832.7  5.6 10
3 Model 2 and age on V1*  2856.4  23.6 11
4 Model 3 and plasma-derived products on CL  2876.6  20.3 12
5 Model 4 and plasma-derived product on V1  2897.6  20.9 13
6 Model 5 and moderate patient, as compared with severe patient on V1  2905.3  7.7 14
Covariate relationships – backward deletion
7 Model 6 without moderate patient, as compared with severe patient on V1  2897.6 7.7 13
8 Model 6 without age on CL  2881.4 23.9 13
9 Model 6 without age on V1  2883.2 22.1 13
10 Model 6 without plasma-derived products on CL  2871.8 33.5 13
11 Model 6 without plasma-derived products on V1  2880.3 25.0 13
OFV indicates objective function value, as calculated by minus two times the logarithm of the likelihood ( 2LL) of the model describing the
data; dOFV, difference of the corresponding OFVs; CL, clearance; ND, not determined; No., number; V1, volume of distribution of the central
compartment. *For these models, the coefficients for covariate age on both CL and V1 were estimated using a piecewise linear model. How-
ever, the slope for the ages above 33.6 years was fixed to 0. Therefore, the number of parameters only increases by 1.
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intervals, as presented by blue and red areas. As a result,
the simulated data were similar to the measured data,
confirming the adequacy of the final model.
Comparison with non-surgical models
Table S2 summarizes population PK parameters of four
models that have been published previously and were
constructed using data obtained after non-surgical dos-
ing. Higher values for the population PK parameter CL
were found for the rFIX models as compared with the
pdFIX models. Figure S2 shows the predicted FIX levels
as obtained using the population PK parameter values
analogous to Fig. 3(A) (without IIV). Figure S2(A,B)
was constructed using solely the pdFIX data from this
study; concentrations were predicted using the popula-
tion parameters of pdFIX model 1 and 2. Likewise, Fig-
ure S2(C,D) was constructed using solely the rFIX data
from this study in combination with population parame-
ters from rFIX model 1 and 2. In each case, the non-
surgical models underpredicted the observed levels, as
shown by the blue lines being above the black line
y = x. The rMPE values, calculated for pdFIX model 1
and 2 and rFIX model 1 and 2, were  7.2%,
 15.7%,  40.7% and  40.3%, respectively. Further-
more, the half-lives calculated for pdFIX and rFIX
using the population parameter values for the final
model from the present study were 51 and 49 h, respec-
tively, whereas the terminal elimination half-lives for
pdFIX model 1 and 2 and rFIX model 1 and 2 were:
28, 23, 20 and 20.3 h, respectively.
Discussion
In this study, the PK of pdFIX and rFIX were character-
ized in children and adults with severe and moderate
hemophilia B undergoing a surgical procedure. Consider-
able interpatient variability was identified for clearance
and central volume of distribution, which was partially
explained by the patient’s age, type of FIX product and
the severity of hemophilia. Importantly, the perioperative
PK parameter of FIX was different from that in the non-
surgical situation.
In population PK analysis, the variability within and
between patients is quantified and, subsequently,
explained using covariates such as age or bodyweight.
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When these variabilities are assessed adequately, a popu-
lation PK model may be used for PK-guided dosing using
Bayesian analysis. In contrast to dosing based on body-
weight, PK-guided dosing allows for individualization of
doses while taking the individual’s PKs into account. To
apply Bayesian analysis clinically, an appropriate popula-
tion PK model is essential. Moreover, Bayesian analysis
using a population PK model, which does not describe
the PKs of FIX adequately, may result in biased individ-
ual PK parameters and, hence, biased estimated doses.
For FVIII, a dedicated population PK model for hemo-
philia A patients undergoing a surgical procedure was
constructed in a similar fashion [27]. Therefore, a dedi-
cated population PK model was constructed to describe
the perioperative FIX levels.
In this study, the observed presurgical FIX level was
higher than the endogenous baseline value in 138 of 255
surgical procedures. These elevated presurgical FIX levels
were taken into account by a virtual dose that was esti-
mated using a typical value and both IIV and IOV.
Thereby, each patient having a presurgical FIX level can
have a different virtual dose for each surgical procedure.
Inclusion of these presurgical FIX levels greatly improved
the fit of the model. Therefore, exclusion of such presur-
gical FIX levels may lead to biased population PK
parameter estimates.
In the present study, age partially explained the inter-
individual variability from CL and V1. In the final model,
the best fit was obtained using a piecewise linear relation
using two slopes with  0.89% and  1.15% for ages
below 34 years for bodyweight-normalized CL and V1,
respectively. Allometric scaling of CL using an exponen-
tial factor of 0.75 partly explains the increased clearance
when a lower bodyweight is present. Nevertheless, addi-
tional variability was explained by taking age into
account. Bj€orkman et al. reported a similarly piecewise
linear relationship between age and CL of rFIX when
administered in a non-surgical situation [28,29]. It was
shown that clearance and (steady-state) volume of distri-
bution decreased when age increased from 2 to 20 years.
Above an age of 20 years, there was virtually no change
in clearance or volume of distribution. Suzuki et al.
explored a similar piecewise relationship of age with CL
for the population PKs of rFIX as well [13]. However, a
relationship between age and CL could not be identified
when bodyweight was included in the model as well. Fur-
thermore, in the covariate analysis, severity of hemophilia
B was associated with V1. For a moderate hemophilia B
patient, V1 was 10.5% lower as compared with a severely
affected patient, which is in agreement with the findings
from Ewenstein et al. [30].
In previous studies, differences have been reported
between PK parameters from pdFIX and rFIX products
in the non-surgical situation [5,30,31]. The in vivo recov-
ery for rFIX products was found to be on average 53%
that of pdFIX products [5]. As in vivo recovery is
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inversely related to volume of distribution, V1 is lower
for pdFIX products. Moreover, the clearance of rFIX
products was found to be approximately twice as high as
compared with pdFIX products [32]. In the present study,
CL and V1 of pdFIX were 11.2% and 17.3% lower than
their respective values for rFIX. These higher values for
CL and V1 from rFIX are in accordance with results
from previous studies. However, the difference between
the types of products is smaller in the surgical situation
than in the non-surgical situation.
In Figure S2, each published non-surgical population
PK model showed that the observed perioperative FIX
levels were underpredicted. These differences were also
demonstrated by simulations of the typical FIX level vs.
time profiles for a patient receiving 100 IU kg1 of
pdFIX or rFIX using the available population PK models
(Figure S5). The calculated rMPEs and half-lives clearly
demonstrate that the PK of FIX in the non-surgical set-
ting is different from the surgical setting. The extent of
underprediction was higher for rFIX model 1 and 2
( 40.7% and  40.3%) compared with pdFIX model 1
and 2 ( 7.2% and  15.7%). This may be explained by
the fact that CL in the non-surgical situation was almost
twice as high as the value in the present study:
560 mL h170 kg1 and 551 mL h170 kg1 vs.
284 mL h170 kg1, respectively. For the pdFIX models,
there was less underprediction. Values for CL in the non-
surgical situation were slightly higher than the values
from the present study: 290 mL h170 kg1 and
319.8 mL h170 kg1 vs. 284 mL h170 kg1. An expla-
nation for this difference is unknown. Nevertheless, the
currently published population PK models for prophylac-
tic treatment with rFIX and pdFIX underpredict the peri-
operative FIX levels. Consequently, use of these models
in the perioperative situation results in overdosing.
Conclusion
In the present study, a population PK model was estab-
lished that adequately described the perioperative FIX
levels obtained from hemophilia B patients undergoing a
surgical procedure. As differences in the population PK
parameters were found between the surgical and non-sur-
gical setting, the dedicated population PK model con-
structed in this study may be applied for patient-tailored
dosing in the perioperative period. However, application
of a population PK model for clinical use should always
be validated.
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